Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


FDA allows continued sale of generic Opana painkiller

The agency determined that a newer version of the drug was not better at deterring abuse

The Food and Drug Administration (FDA) announced Friday that it will allow the continued sale of generic forms of the prescription pain drug Opana ER, after the agency found that a new form of the drug was not significantly more successful at preventing abuse.

Opana, which is manufactured by Endo Health Solutions, is an extended-release narcotic. These types of drugs are popular among addicts, who crush the pills in an effort to snort or inject the full dose all at once.

Last month, the FDA blocked the sale of generic versions of Purdue Pharma's OxyContin after the agency ruled that a newer, tamper-resistant version of the pain pills was more effective at deterring abuse. But Endor Health Solutions had no such luck, even after it relaunched Opana ER in 2012 with a new anti-crush design.

Endo argued to the FDA that users were abusing older versions of Opana 80 percent more often than they misused the new painkiller. But, although the FDA said that it would “continue to encourage the development of abuse-deterrent formulations of opioids,” it declined to stop sales of generic Opana versions.

"Reformulated Opana ER can be readily prepared for injection, despite Endo's claim," the FDA said in a statement. "It also appears that reformulated Opana ER can be prepared for snorting using commonly available tools and methods."

Read more at the Wall Street Journal.

For more InsideCounsel coverage of the pharmaceutical industry, see:

FDA issues warning about shortened cancer drug name

FDA considering petition to protect biologic medications’ patents

Generic-drug makers sue brand-name companies for product samples

Novartis cancer drug not innovative enough for patent, India Supreme Court rules

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.